International Journal of Cancer最新文献

{"title":"Experiences of cancer-related stigma in Africa: A scoping review.","authors":"Judith M Mwobobia, Srishti Sardana, Dina Abouelella, Suhana Posani, Leila Ledbetter, Margaret Graton, Nosayaba Osazuwa-Peters, Brandon A Knettel","doi":"10.1002/ijc.35376","DOIUrl":"https://doi.org/10.1002/ijc.35376","url":null,"abstract":"<p><p>Cancer is a major health issue, particularly in low- and middle-income countries where 70% of cancer deaths occur. Stigma and barriers to screening and treatment lead to poor outcomes. We conducted structured searches of PubMed, Embase, MEDLINE, CINAHL, and CABI Global Health databases according to PRISMA-ScR guidelines. Searches used keywords related to (1) Africa, (2) cancer, and (3) stigma. We then screened to finalize a list of research manuscripts, dissertations, theses, and conference abstracts using quantitative, qualitative, or mixed methods to explore cancer stigma in Africa. This review focused on non-cervical cancers. Breast and cervical cancers have distinct stigma-related experiences due to awareness, screening, and sociocultural perceptions. Including cervical cancer risks dilutes the specificity and depth of findings. The review included 53 studies that linked stigma and cancer in Africa to physical symptoms, appearance changes, misconceptions, and emotional challenges, hindering care and worsening treatment outcomes. Cancer-related stigma negatively impacts screening and treatment engagement in Africa. The lack of intervention studies underscores the need for evidence-based strategies to reduce stigma. Future efforts should reduce barriers to cancer care, enhance public awareness, and implement policy changes to improve outcomes.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy and long-term effectiveness of established screening modalities and strategies in colorectal cancer screening: An umbrella review.","authors":"Yuelun Zhang, Kai Song, Yueyang Zhou, Yuqing Chen, Xinran Cheng, Min Dai, Dong Wu, Hongda Chen","doi":"10.1002/ijc.35381","DOIUrl":"https://doi.org/10.1002/ijc.35381","url":null,"abstract":"<p><p>Colorectal cancer (CRC) screening may reduce the disease incidence and mortality. However, there is a lack of comprehensive evaluation of the existing evidence on different screening modalities. We aimed to systematically summarize the diagnostic accuracy and long-term effectiveness of CRC screening. Medline, Embase, and the Cochrane Database of Systematic Reviews were searched from database inception to December 31, 2023. Systematic reviews and meta-analyses of the diagnostic accuracy of colonoscopy, flexible sigmoidoscopy (FS), guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test (FIT), multi-target stool DNA (mt-sDNA) testing, plasma Septin9 methylation (mSEPT9), computed tomography colonography (CTC) using colonoscopy as the reference standard, or evaluating the long-term effectiveness of incidence and mortality of CRC screening strategies were eligible. Combined accuracy and long-term effectiveness were extracted. The level of evidence was evaluated using GRADE. Using colonoscopy as the reference standard, CTC had the highest sensitivity for detecting CRC and precursors, followed by mt-sDNA, FIT, mSEPT9, and gFOBT, all of which had satisfying specificities (>85%). Convincing evidence showed FS screening reduced CRC incidence and CRC-related mortality, and gFOBT screening reduced CRC mortality but not incidence. Moderate evidence suggested colonoscopy and FIT screening were associated with reduced CRC incidence and mortality. CRC screening was not associated with the reduction of all-cause mortality and non-CRC mortality. Strong variations of diagnostic accuracy existed for the established non-invasive CRC screening methods. Consistent evidence demonstrated the effectiveness of screening in preventing CRC-related death, but convincing evidence was restricted to FS and gFOBT.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy and pregnancy outcomes after adolescent and young adult cancer in the AYA horizon study.","authors":"Hazel B Nichols, Chelsea Anderson, Christopher D Baggett, Nancy T Cannizzaro, Stephanie M Engel, Darios Getahun, Laura Green, Marilyn L Kwan, Cecile A Laurent, Barbara Luke, Jennifer E Mersereau, Sara Mitra, Lisa M Moy, Ethan Wantman, Carey K Anders, Steven D Spandorfer, Andrew B Smitherman, William A Wood, Lanfang Xu, Xi Zhou, Chun R Chao, Lawrence H Kushi","doi":"10.1002/ijc.35383","DOIUrl":"https://doi.org/10.1002/ijc.35383","url":null,"abstract":"<p><p>Lower birth rates and higher pregnancy loss are observed after childhood cancer. Studies specific to adolescent and young adult (AYA) cancer rarely have information on pregnancies that do not end in live birth, fertility preservation strategies, or detailed cancer treatment information to assess these risks. To address this gap, we examined pregnancy outcomes after cancer in a cohort of 30,020 AYAs with detailed clinical records. We identified 6021 survivors of AYA cancer matched to 23,999 AYAs without cancer enrolled in the Kaiser Permanente California health systems during 2004-2016. Of these, 950 survivors had ≥1 pregnancy during follow-up through 2018. Hazard ratios (HR) and 95% confidence intervals (CI) for pregnancy were estimated using multivariable subdistribution hazard models accounting for competing risks. Relative risks (RR) and 95% CIs for pregnancy loss were calculated with multivariable Poisson regression with generalized estimating equations. Pregnancy was less common after AYA breast (HR = 0.57; 95% CI: 0.50, 0.66) or gynecologic cancer (HR = 0.55; 95% CI: 0.42, 0.73) compared to AYAs without cancer. Among AYAs with cancer, some alkylating and platinum chemotherapy agents, but not gonadotoxic radiation, were associated with a lower likelihood of pregnancy. Use of assisted reproductive technologies was not common, and 69% of pregnancies after AYA cancer resulted in live birth. Pregnancy loss was not statistically significantly elevated for any cancer type. Among survivors, pregnancy loss was more common at older ages, with smoking during pregnancy, and among those who received cyclophosphamide. Our findings inform reproductive counseling and prenatal care for reproductive age cancer survivors.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and optimal duration of maintenance immunotherapy following systemic chemoimmunotherapy and locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A multicenter retrospective cohort study.","authors":"Yujun Hu, Tianzhu Lu, Hao Zhang, Bijuan Chen, Jianji Pan, Jingao Li, Xiaochang Gong, Hui Li, Yingying Huang, Nian Lu, Yujing Liang, Liangru Ke, Chuanmiao Xie","doi":"10.1002/ijc.35382","DOIUrl":"https://doi.org/10.1002/ijc.35382","url":null,"abstract":"<p><p>This study evaluates the efficacy, optimal duration, and target population for maintenance immunotherapy (MI) in patients with de novo metastatic nasopharyngeal carcinoma (dmNPC) who have achieved disease control following systemic treatment. A multicenter retrospective cohort study included 258 patients whose disease was controlled after chemoimmunotherapy and locoregional radiotherapy. The primary outcome was progression-free survival (PFS), with conditional survival and restricted mean survival time (RMST) analyses used to determine the optimal MI duration. Immune infiltration was assessed via multiplex immunohistochemistry. The results showed that the 2-year PFS was significantly higher in the MI group compared to the non-MI group (69.7% vs. 53.5%, p = .02). Multivariable analysis showed MI was an independent predictor of improved PFS (HR: 0.581, p = .006). Conditional survival and RMST analyses confirmed a significant improvement in PFS with MI continuation within 15 months. Patients with high densities of CD3+ T cells (HR: 0.546, p = .023), CD20+ B cells (HR: 370, p < .001), and a high percentage of PD-L1+ tumor cells (HR: 0.440, p = .006) had significantly better PFS compared to those with lower levels. Furthermore, MI was particularly beneficial for patients with lower densities of CD3+ T cells (p = .018), CD20+ B cells (p < .001), and lower PD-L1+ tumor cell percentages (p < .001), while this benefit was not observed in patients with higher immune infiltration levels. In conclusion, a 15-month duration of MI significantly improves PFS in patients with dmNPC after systemic treatment. Patients with lower levels of immune infiltration tend to have poorer PFS but appear to gain greater benefit from MI.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143481942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study.","authors":"Ala Jabri Haug, Nathalie Støer, Hilde Langseth, Franziska Siafarikas, Edoardo Botteri, Renée Turzanski Fortner, Kristina Lindemann","doi":"10.1002/ijc.35363","DOIUrl":"https://doi.org/10.1002/ijc.35363","url":null,"abstract":"<p><p>While nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to improve survival in certain cancers, data in patients with endometrial cancer (EC) is conflicting. This study investigated use of aspirin and nonaspirin NSAIDs (NA-NSAIDs) and EC-specific-and all-cause death. This nationwide cohort study linked data from the Cancer Registry of Norway with The Norwegian Prescription database. Patients diagnosed with EC from 2004 to 2018 were included. Post-diagnosis exposure to aspirin and NA-NSAIDs was defined as ≥3 consecutive prescriptions ≥30 days after EC diagnosis, with pre-diagnosis use as ≥2 filled prescriptions <6 months prior to diagnosis. Follow-up started 10 months after diagnosis. Hazard ratios for the risk of death were calculated with multivariable Cox-regression models. Our study population included 7751 individuals with EC, 685 (9%) were aspirin users and 620 (8%) were NA-NSAIDs users. The median follow-up time was 5.0 years, with 1518 (20%) deaths observed (n = 728 (9%) EC-specific). In multivariable analysis, aspirin use was significantly associated with a 19% higher risk of all-cause death compared to non-users (HR = 1.19, 95% CI [1.01-1.41]). The association was stronger among combined pre- and postdiagnosis use (HR = 1.35 [1.12-1.64]). NA-NSAIDs use increased risk of cancer-related death (HR = 1.25 [0.99-1.58]) and there was a dose-response association with significantly higher risk of cancer-specific death with higher cumulative doses (HR = 1.33 [1.02-1.75]). We found a higher risk of cancer-specific-and all-cause death among patients that used aspirin and NA-NSAIDs after a diagnosis of EC. Further studies on the biological mechanisms underlying these associations are needed.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polyamine depletion limits progression of acute leukaemia.","authors":"Weiman Gao, Mawar Karsa, Lin Xiao, Dayna Spurling, Ayu Karsa, Emma Ronca, Angelika Bongers, Xinyi Guo, Chelsea Mayoh, Mujahid Azfar, Steven H L Verhelst, Katsunori Tanaka, Laurence C Cheung, Rishi S Kotecha, Richard B Lock, Mark R Burns, Peter Vangheluwe, Murray D Norris, Michelle Haber, Klaartje Somers","doi":"10.1002/ijc.35362","DOIUrl":"https://doi.org/10.1002/ijc.35362","url":null,"abstract":"<p><p>Cancer cells are addicted to polyamines, polycations essential for cellular function. While dual targeting of cellular polyamine biosynthesis and polyamine uptake is under clinical investigation in solid cancers, preclinical and clinical studies into its potential in haematological malignancies are lacking. Here we investigated the preclinical efficacy of polyamine depletion in acute leukaemia. The polyamine biosynthesis inhibitor difluoromethylornithine (DFMO) inhibited growth of a molecularly diverse panel of acute leukaemia cell lines, while non-malignant cells were unaffected. Responsiveness to DFMO was linked to decreased levels of its molecular target, the rate-limiting polyamine biosynthesis enzyme ODC1, and of the polyamine transporters ATP13A2 and ATP13A3. DFMO increased polyamine uptake and upregulated expression of polyamine transporters in acute leukaemia cells, a compensatory effect abolished by treatment with the polyamine transport inhibitor AMXT 1501. This drug, currently in a phase 1 clinical trial in solid tumours in combination with DFMO, potentiated the inhibitory effects of DFMO, and their combination synergistically inhibited the growth of acute leukaemia cell lines by inducing apoptosis. DFMO and AMXT 1501 limited disease progression in highly aggressive xenograft models of infant KMT2A-rearranged leukaemia, even when treatment was initiated at high disease burden. Increased expression of c-MYC was associated with enhanced sensitivity to the combination of DFMO and AMXT 1501, suggesting this oncoprotein as a potential predictive marker of response to the drug combination. In conclusion, targeting polyamine biosynthesis and polyamine uptake limits disease progression in models of acute leukaemia, supporting further preclinical and clinical investigation into this approach for acute leukaemia.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult brain cancer incidence patterns: A comparative study between Japan and Japanese Americans.","authors":"Byron Sigel, Diana R Withrow, Lene H S Veiga, Eiko Saito, Tomohiro Matsuda, Kota Katanoda","doi":"10.1002/ijc.35374","DOIUrl":"https://doi.org/10.1002/ijc.35374","url":null,"abstract":"<p><p>Adult primary brain and central nervous system (CNS) cancers, though comprising only about 4% of new cancer diagnoses, significantly impact morbidity and mortality due to their low survival rates. Globally, brain and CNS tumor incidence varies considerably, with the United States exhibiting one of the highest rates and Japan among the lowest worldwide. In the United States, incidence rates differ by race, with higher rates in non-Hispanic whites (NHW) and lower rates in Asian Americans and Pacific Islanders (AAPI). This study examines the incidence of malignant CNS tumors in Japan and Japanese Americans, comparing these groups to NHW and AAPI populations in the United States. We estimated age-standardized incidence rates (ASR) of brain and CNS tumors among adults using data from the Monitoring of Cancer Incidence in Japan (MCIJ) and the U.S. Surveillance, Epidemiology, and End Results (SEER)-9 registries from 2007 to 2014. Incidence rates were stratified by age, sex, and specific CNS tumor subtypes. Incidence rates of CNS tumors among Japanese (ASR: 3.66, 95% CI: 3.56-3.76) and Japanese Americans (ASR: 2.5, 95% CI: 2.13-3.05) were lower than among NHW (9.43, 95% CI, 9.31-9.56) and AAPI populations (ASR: 4.13, 95% CI: 3.94-4.33) in the United States. The same pattern was observed for CNS tumor subtypes and across age groups and sex. This study supports a genetic component in the risk of brain and CNS tumors, a cancer type with largely unknown etiology. By comparing incidence rates across populations, it contributes to understanding the balance of genetic and environmental risk factors in the development of these cancers.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence trends and relative survival of colorectal neuroendocrine neoplasms: A population-based study using German cancer registry data.","authors":"Lennart Möller, Andras Szentkirályi, Christine Eisfeld, Ina Wellmann, Franziska Rees, Kevin Claaßen, Florian Oesterling, Hiltraud Kajüter, Andreas Stang","doi":"10.1002/ijc.35372","DOIUrl":"https://doi.org/10.1002/ijc.35372","url":null,"abstract":"<p><p>Neuroendocrine neoplasms (NENs) of the colon and rectum are a heterogeneous group of epithelial neoplasms with neuroendocrine differentiation. They include well-differentiated neuroendocrine tumors (NETs), poorly differentiated neuroendocrine carcinomas (NECs) and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs). Our aim was to calculate incidence, incidence trends and relative survival for colonic and rectal NETs, NECs, and MiNENs. We analyzed data covering the entire German population recorded between 2009 and 2021, calculating age-standardized incidence rates, annual percent changes, and the relative 5-year survival probability for the calendar period 2017-2021. Our comprehensive analyses included 12,602 NEN cases, with 59% located in the rectum. NECs, MiNENs and tumors with colonic location showed higher stages. We observed an increase in the incidence of NETs, particularly in patients aged <55 years, and in the incidence of MiNENs, and a constant incidence of NECs. The relative five-year survival was high for rectal NETs (95.9%, 95%-CI 94.6; 97.1) and colonic NETs (81.4%, 95%-CI 78.3; 84.5) and low for colonic NECs (20.5%, 95%-CI 17.6; 23.4) and rectal NECs (19.2%, 95%-CI 15.7; 22.6). The increase in the incidence of NETs might be partly due to colorectal cancer screening, improved diagnostics, and changes in classification of NETs. We attribute the increase in incidence of MiNENs to the recent introduction of this morphological category. Higher stages at diagnosis, a higher proportion of NECs and higher median age at diagnosis may contribute to the less favorable survival probabilities associated with colonic as opposed to rectal location.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and validation of a transcription factor regulatory network-based signature for individualized prognostic risk in lung adenocarcinoma.","authors":"Kai Wang, Jun Xiang, Jun Zhou, Congcong Chen, Zhoufeng Wang, Na Qin, Meng Zhu, Lingfeng Bi, Linnan Gong, Liu Yang, Yingjia Chen, Xianfeng Xu, Juncheng Dai, Hongxia Ma, Zhibin Hu, Weimin Li, Cheng Wang, Guangfu Jin, Hongbing Shen","doi":"10.1002/ijc.35375","DOIUrl":"https://doi.org/10.1002/ijc.35375","url":null,"abstract":"<p><p>Despite significant progress in diagnostic and therapeutic modalities, lung adenocarcinoma (LUAD) still exhibits a high recurrence risk and a low 5-year survival rate. Reliable prognostic signatures are imperative for risk stratification in LUAD patients. This study encompassed 2740 patients from 23 LUAD cohorts, including one single-cell RNA sequencing (scRNA-seq) dataset, five bulk RNA-seq datasets, and 17 microarray datasets. Using scRNA-seq dataset, we defined a group of epithelial-specific transcription factors significantly over-represented in the epithelial-to-mesenchymal transition (EMT) gene set (enrichment ratio [ER] = 5.80, Fisher's exact test p < .001), and the corresponding target genes were significantly enriched in the cancer driver gene set (ER = 2.74, p < .001), indicating of their crucial roles in the EMT process and tumor progression. We constructed a single-cell gene pairs (scGPS) signature, composed of 3521 gene pairs derived from the epithelial cell-specific transcription factor regulatory network, to predict overall survival (OS) of LUAD. High-risk patients identified by scGPS in the discovery cohort exhibited significantly worse OS compared to low-risk patients (Hazard ratio [HR] = 1.78, 95% CI: 1.29-2.46, log-rank p = 1.80 × 10^-4). The scGPS outperformed other established gene signatures and demonstrated robust prognostic stratification across various independent datasets, including microarray data and even early-stage LUAD patients. It remained an independent prognostic factor after adjusting for clinical and pathologic factors. In addition, combining scGPS with tumor stage further enhanced prognostic accuracy compared to using stage alone. The scGPS signature offers individualized prognosis estimations, showing significant potential for practical application in clinical settings.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143439665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of a nationwide colorectal cancer screening program on the incidence of synchronous colorectal peritoneal metastases.","authors":"Laskarina J K Galanos, Anouk Rijken, Marloes A G Elferink, Niels F M Kok, Felice N van Erning, Ignace H J T De Hingh","doi":"10.1002/ijc.35356","DOIUrl":"https://doi.org/10.1002/ijc.35356","url":null,"abstract":"<p><p>This study aims to assess the influence of colorectal cancer screening on the incidence of synchronous colorectal peritoneal metastases (CPM). Patients diagnosed with CPM between 2009 and 2022 were selected from the Netherlands Cancer Registry. Crude rates of the observed and expected CPM incidence were calculated per 100,000 individuals and compared. Expected incidence was extrapolated from the incidence in the years prior to screening invitation. In total, 9,238 patients with CPM were included. For the screen-eligible population (55-75 years), the observed CPM incidence increased from 5.1 (2009) to 7.0 before screening initiation (2013) (Annual percent change [APC] 8.2%, p = .014). Since the start of screening, the observed CPM incidence stabilized: 8.8 (2014) to 8.9 (2022) (APC -1.0%, p = .159). Within the total population, the observed CPM incidence before screening showed an increase from 3.6 (2009) to 4.0 (2013) (APC 3.4%, p = .050). Since screening, a decrease in CPM incidence was observed from 4.4 (2014) to 3.5 (2022) (APC -2.2%, p = .010). The observed and expected number of CPM differed significantly in the screen-eligible population (6,437 observed vs. 7,992 expected individuals; p < .001) and in the overall Dutch population (9,238 observed vs. 10,440 expected individuals; p < .001). In conclusion, a declining trend was observed in the incidence of CPM in the Dutch population since the start of colorectal cancer screening. The observed incidence was lower compared to the expected incidence, both in the screen-eligible population and in the overall population. These findings suggest that screening results in a decrease of patients diagnosed with CPM possibly resulting in an improved survival of colorectal cancer patients.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143439669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}